It is one of GSK's top drugs, with sales of $2.2 billion last ... "Today's data, along with recent phase III data in severe asthma, will be used in regulatory filings around the world." ...
GSK plc GSK announced ... 2 studies showed that treatment with depemokimab resulted in statistically significant and clinically meaningful reductions in exacerbations (asthma attacks) over 52 ...